Emerald Health Therapeutics Delivers to Yukon and Adds Supply Agreements with Alberta and Saskatchewan
March 29 2019 - 6:00AM
Emerald Health Therapeutics, Inc. (“Emerald”) (TSXV: EMH; OTCQX:
EMHTF) has fulfilled its first purchase order of cannabis from
Yukon Liquor Corporation, signed a sales agreement with Alberta
Gaming, Liquor and Cannabis (AGLC), and become officially
registered by the Saskatchewan Liquor and Gaming Authority (SLGA)
to supply cannabis to the Saskatchewan market. First shipments to
Alberta and Saskatchewan are expected in April.
“We are pleased to provide our Emerald-branded
cannabis products to the adult-use markets in Alberta, Saskatchewan
and the Yukon,” said Dr. Avtar Dhillon, President and Executive
Chairman of Emerald. “This brings the number to five provinces and
one territory across Canada and is another step in our sales
strategy to become a reliable national recreational cannabis
supplier.”
Emerald is consistently meeting its supply
commitments in Ontario, British Columbia, and Newfoundland and
Labrador, and is advancing prospective supply agreements with all
remaining provinces and territories in order to develop a
significant presence in the recreational market.
Emerald’s cannabis supply is provided by its
Verdélite indoor facility in Saint Eustache, Québec, and Pure
Sunfarms, its 50%-owned joint venture in BC that is licensed to
cultivate in 1.03 million square feet of its 1.1 million square
foot greenhouse. This facility has been scaling up production over
the last four quarters and will be fully planted in April. Emerald
is working to expand sources and volume of indoor, greenhouse and
outdoor-grown cannabis and hemp. In 2018, Emerald acquired 500
acres of harvested hemp and expects to purchase 1,000 acres of
harvested hemp in 2019.
About Emerald Health Therapeutics,
Inc. Emerald Health Therapeutics is a Canadian licensed
producer of cannabis with operations in British Columbia and
Québec. Emerald has secured exclusive strategic partnerships for
large scale extraction and softgel encapsulation, as well as for
proprietary technology to enhance cannabinoid bioavailability. Its
team is highly experienced in life sciences, product development,
large-scale agri-business, and marketing, and is focused on
developing proprietary, value-added cannabis products for medical
and adult-use customers.
Emerald is part of the Emerald Group, which
represents a broad array of companies focused on developing
pharmaceutical, botanical, and nutraceutical products developed to
provide wellness and medical benefits by interacting with the human
body’s endocannabinoid system.
Please visit www.emeraldhealth.ca for more information or
contact: Rob Hill, Chief Financial Officer (800) 757 3536 Ext. #
5
Emerald Investor Relations (800) 757 3536 Ext.
#5invest@emeraldhealth.ca
Neither the TSX Venture Exchange nor its
Regulation Services Provider (as that term is defined in the
policies of the TSX Venture Exchange) accepts responsibility for
the adequacy or accuracy of this release.
Cautionary Note Regarding Forward-Looking
Statements: Certain statements made in this press release that are
not historical facts are forward-looking statements and are subject
to important risks, uncertainties and assumptions, both general and
specific, which give rise to the possibility that actual results or
events could differ materially from our expectations expressed in
or implied by such forward-looking statements. Such statements
include projected job creation figures at our operating facilities;
production and processing capacity of various facilities; expansion
of facilities; and anticipated production costs.
We cannot guarantee that any forward-looking
statement will materialize, and readers are cautioned not to place
undue reliance on these forward-looking statements. These
forward-looking statements involve risks and uncertainties related
to, among other things, failure to obtain regulatory approvals;
failure to obtain necessary financing; results of production and
sale activities; results of scientific research; regulatory
changes; changes in prices and costs of inputs; demand for labour;
demand for products; as well as the risk factors described in the
Company’s annual information form and other regulatory filings. The
forward-looking statements contained in this press release
represent our expectations as of the date hereof. Forward-looking
statements are presented for the purpose of providing information
about management's current expectations and plans and allowing
investors and others to obtain a better understanding of our
anticipated operating environment. Readers are cautioned that such
information may not be appropriate for other purposes. The Company
undertakes no obligations to update or revise such statements to
reflect new circumstances or unanticipated events as they occur,
unless required by applicable law.
Emerald Health Therapeut... (TSXV:EMH)
Historical Stock Chart
From Mar 2024 to Apr 2024
Emerald Health Therapeut... (TSXV:EMH)
Historical Stock Chart
From Apr 2023 to Apr 2024